Page 689 - Read Online

Zaichick et al. J Cancer Metastasis Treat 2019;5:48 I http://dx.doi.org/10.20517/2394-4722.2019.07 Page 7 of 9

that this method is an adequate analytical tool for the non-destructive determination of Br, Fe, Rb, Sr, and Zn
concentration in the EPF samples of human prostate. It was observed that in the EPF of cancerous prostate
contents of Rb and Zn significantly lower in a comparison with those in the EPF of hyperplastic prostate.
In our opinion, the decrease in levels of Rb and Zn in the EPF of cancerous prostate might demonstrate an
involvement of these TE in etiology and pathogenesis of malignant prostate tumors. It was supposed that the
changes of Rb and Zn levels in the EPF samples can be used as tumor markers.

DECLARATIONS
Acknowledgments
The authors are extremely grateful to Dr Tatyana Sviridova, Medical Radiological Research Center, Obninsk
for supplying EPF samples.

Authors’ contributions
Collected EPF samples, designed the EDXRF of samples, and carried out the statistical analysis of results:
Zaichick V
Managed the literature searches, wrote the first draft of the manuscript, and translated the manuscript into
English: Zaichick S
Read and approved the final manuscript: Zaichick V, Zaichick S

Availability of data and materials
Not applicable.

Financial support and sponsorship
None.

Conflicts of interest
Both authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
All studies were approved by the Ethical Committees of the Medical Radiological Research Centre, Obninsk.
All procedures performed in studies involving human participants were in accordance with the ethical
standards of the institutional and/or national research committee and with the 1964 Helsinki declaration
and its later amendments or comparable ethical standards.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2019.

REFERENCES
1. Rebbeck TR, Haas GP. Temporal trends and racial disparities in global prostate cancer prevalence. Can J Urol 2014;21:7496-506.
2. Wong MCS, Goggins WB, Wang HHX, Fung FDH, Leung C, et al. Global incidence and mortality for prostate cancer: analysis of
temporal patterns and trends in 36 countries. Eur Urol 2016;70:862-74.
3. Rebbeck TR. Conquering cancer disparities: new opportunities for cancer epidemiology, biomarker, and prevention research. Cancer
Epidemiol Biomarkers Prev 2006;15:1569-71.
4. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, et al. Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26.
5. Carter HB, Coffey DS. The prostate: an increasing medical problem. Prostate 1990;16:39-48.
6. Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. Lancet 1991;338:469-71.